Literature DB >> 26677139

Regulation of cyclic AMP response element-binding protein during neuroglial interactions.

LiMei Qin1, Ron Bouchard1,2, Subbiah Pugazhenthi1,2.   

Abstract

Communications between neurons and glial cells play an important role in regulating homeostasis in the central nervous system. cAMP response element-binding protein (CREB), a transcription factor, is down-regulated by neurotoxins, which are known to be released by activated glial cells. To determine the role of CREB signaling in neuroglial interactions, we used three neuroglial coculture models consisting of human neuroprogenitor cell (NPC)-derived neurons and human microglia. Conditioned medium from the Abeta (Aβ)-activated microglia decreased CREB phosphorylation and brain-derived neurotrophic factor promoter activity (47%), whereas the same medium induced (p < 0.01) the promoter of CXCL10, a chemokine, in NPC-derived neuron-rich cultures. These effects were reversed when microglia were exposed to Aβ in the presence of minocycline, an anti-inflammatory agent. The expression of CREB targets, including brain-derived neurotrophic factor, synapsin-1, and BIRC3 decreased by 50-65% (p < 0.01) in neurons isolated by laser capture microdissection in close proximity of microglia in neuroglial mixed cultures. Neuronal survival actively modulated microglial behavior when neurons and microglia were cocultured side-by-side on semicircles of ACLAR membrane. Neuronal injury, caused by the over-expression of dominant negative form of CREB, exacerbated Aβ-mediated microglial activation, whereas CREB over-expression resulted in decreased microglial activation. Decreases in the levels of neuronal markers were observed when NPCs were differentiated in the presence of proinflammatory cytokines IL-1β, tumor necrosis factor α, or IL-6. Instead, the NPCs differentiated into a glial phenotype, and these effects were more pronounced in the presence of tumor necrosis factor α. Our findings suggest that CREB down-regulation is an important component of defective neuroglial communications in the brain during neuroinflammation. Neuroglial interactions were examined using coculture models of human neuroprogenitor cell-derived neurons and microglia isolated from human fetal brain. A novel coculture model of neurons and microglia cultured on ACLAR membranes in the same dish was also included. In this model, over-expression of the dominant negative mutant form of the transcription factor CREB in neurons induced neuronal apoptosis and microglial activation whereas expression of the wild type form of CREB resulted in protection of neurons and suppressed microglial activity, thereby suggesting that neurons play an active role in neuroglial interactions.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  Alzheimer's disease; CREB; human neuroprogenitor cells; microglia; neuroinflammation; signal transduction

Mesh:

Substances:

Year:  2016        PMID: 26677139     DOI: 10.1111/jnc.13497

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

Review 1.  Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.

Authors:  Subbiah Pugazhenthi; Limei Qin; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-05-06       Impact factor: 5.187

Review 2.  Nuclear Factor-Kappa B and Alzheimer Disease, Unifying Genetic and Environmental Risk Factors from Cell to Humans.

Authors:  Simon Vann Jones; Ilias Kounatidis
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

3.  Inhibiting the microglia activation improves the spatial memory and adult neurogenesis in rat hippocampus during 48 h of sleep deprivation.

Authors:  Meetu Wadhwa; Amit Prabhakar; Koushik Ray; Koustav Roy; Punita Kumari; Prabhash Kumar Jha; Krishna Kishore; Sanjeev Kumar; Usha Panjwani
Journal:  J Neuroinflammation       Date:  2017-11-15       Impact factor: 8.322

4.  SIRT3 deficiency-induced mitochondrial dysfunction and inflammasome formation in the brain.

Authors:  Alpna Tyagi; Christy U Nguyen; Thomas Chong; Cole R Michel; Kristofer S Fritz; Nichole Reisdorph; Leslie Knaub; Jane E B Reusch; Subbiah Pugazhenthi
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

Review 5.  Physical Exercise Inhibits Inflammation and Microglial Activation.

Authors:  Onanong Mee-Inta; Zi-Wei Zhao; Yu-Min Kuo
Journal:  Cells       Date:  2019-07-09       Impact factor: 6.600

6.  Neurological Enhancement Effects of Melatonin against Brain Injury-Induced Oxidative Stress, Neuroinflammation, and Neurodegeneration via AMPK/CREB Signaling.

Authors:  Shafiq Ur Rehman; Muhammad Ikram; Najeeb Ullah; Sayed Ibrar Alam; Hyun Young Park; Haroon Badshah; Kyonghwan Choe; Myeong Ok Kim
Journal:  Cells       Date:  2019-07-21       Impact factor: 6.600

Review 7.  FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective.

Authors:  Patrizia Pignataro; Manuela Dicarlo; Roberta Zerlotin; Chiara Zecca; Maria Teresa Dell'Abate; Cinzia Buccoliero; Giancarlo Logroscino; Silvia Colucci; Maria Grano
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 8.  PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity.

Authors:  Ben Rombaut; Sofie Kessels; Melissa Schepers; Assia Tiane; Dean Paes; Yevgeniya Solomina; Elisabeth Piccart; Daniel van den Hove; Bert Brône; Jos Prickaerts; Tim Vanmierlo
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

9.  Metabolic syndrome exacerbates amyloid pathology in a comorbid Alzheimer's mouse model.

Authors:  Alpna Tyagi; Carol Mirita; Nadine Taher; Iman Shah; Emily Moeller; Anit Tyagi; Thomas Chong; Subbiah Pugazhenthi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-05-30       Impact factor: 5.187

Review 10.  Therapies for Prevention and Treatment of Alzheimer's Disease.

Authors:  J Mendiola-Precoma; L C Berumen; K Padilla; G Garcia-Alcocer
Journal:  Biomed Res Int       Date:  2016-07-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.